Core Viewpoint - The market anticipates New Jersey Resources (NJR) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - NJR is expected to post quarterly earnings of $1.65 per share, reflecting a year-over-year increase of +17.9%, and revenues are projected to be $731.72 million, up 11.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 750% lower in the last 30 days, indicating a significant reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.21%, indicating a likelihood of beating the consensus EPS estimate [10][11]. Historical Performance - In the last reported quarter, NJR exceeded the expected earnings of $1.14 per share by delivering $1.29, resulting in a surprise of +13.16%. Over the last four quarters, the company has beaten consensus EPS estimates two times [12][13]. Investment Considerations - While NJR appears to be a strong candidate for an earnings beat, other factors should also be considered when making investment decisions [14][16].

Company Overview - ADC Therapeutics SA (ADCT) is anticipated to report a year-over-year increase in earnings due to higher revenues for the quarter ended March 2025, with a consensus outlook indicating a quarterly loss of $0.38 per share, reflecting a +32.1% change from the previous year [1][3] - Expected revenues for ADC Therapeutics are projected at $18.15 million, which is a slight increase of 0.6% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 8.33% higher in the last 30 days, indicating a reassessment by analysts of their initial estimates [4] - The Most Accurate Estimate for ADC Therapeutics aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a positive ESP being a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [6][8] - ADC Therapeutics currently holds a Zacks Rank of 3, making it challenging to predict a definitive earnings beat [11] Historical Performance - In the last reported quarter, ADC Therapeutics was expected to post a loss of $0.35 per share but actually reported a loss of $0.29, resulting in a surprise of +17.14% [12] - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Cardiff Oncology (CRDF) is expected to report a loss of $0.19 per share for the same quarter, indicating a year-over-year change of +13.6% [17] - Cardiff Oncology's revenue is projected to be $0.17 million, down 19.1% from the previous year, but it has an Earnings ESP of 24.32% and a Zacks Rank of 2, suggesting a higher likelihood of beating the consensus EPS estimate [18]

Core Viewpoint - The Beachbody Company, Inc. (BODI) is expected to report a year-over-year increase in earnings despite lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The company is projected to post a quarterly loss of $1.33 per share, reflecting a year-over-year change of +30.7% [3]. - Revenues are anticipated to be $63.1 million, down 47.4% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 11.01% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have shown a nearly 70% success rate in delivering positive surprises [8]. Historical Performance - In the last reported quarter, the company was expected to post a loss of $2.88 per share but delivered a loss of $1.89, resulting in a surprise of +34.38% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - The Beachbody Company does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, but other factors should also be considered for investment decisions [16].

Core Viewpoint - Freightcar America (RAIL) is anticipated to report a year-over-year increase in earnings despite a decline in revenues for the quarter ended March 2025, with the actual results being crucial for its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.08 per share, reflecting a significant year-over-year increase of +300%, while revenues are projected to be $121.06 million, a decrease of 24.8% from the previous year [3]. - The consensus EPS estimate has been revised down by 12% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, which complicates predictions of an earnings beat [10][11]. - The stock currently holds a Zacks Rank of 3, indicating a neutral position, which further challenges the likelihood of exceeding the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Freightcar America had an expected EPS of $0.05 but delivered $0.21, resulting in a surprise of +320% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates twice [13]. Conclusion - While the company does not appear to be a strong candidate for an earnings beat, investors should consider other influencing factors when making decisions regarding the stock ahead of the earnings release [16].

Core Viewpoint - Certara, Inc. is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with earnings expected at $0.13 per share, reflecting a 30% increase, and revenues projected at $106 million, a 9.7% rise from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for May 5, and the stock may experience upward movement if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 2.63% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, which complicates predictions of an earnings beat [10][11]. - Certara's Zacks Rank is currently 3 (Hold), which does not strongly indicate a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Certara exceeded the expected earnings of $0.13 per share by delivering $0.15, resulting in a surprise of +15.38% [12]. - Over the past four quarters, Certara has beaten consensus EPS estimates two times [13]. Industry Context - Exact Sciences, a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings of $0.37 per share, reflecting a 26% year-over-year increase, with revenues projected at $689.35 million, an 8.1% increase [17]. - Exact Sciences has an Earnings ESP of 61.75% and a Zacks Rank of 3, indicating a higher likelihood of surpassing the consensus EPS estimate [18].

The market expects Diamondback Energy (FANG) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

Core Viewpoint - Vertex Pharmaceuticals (VRTX) is expected to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended March 2025, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The upcoming earnings report is anticipated to be released on May 5, 2025, with a consensus EPS estimate of $4.22, reflecting an 11.3% decrease year-over-year, while revenues are projected to be $2.82 billion, up 4.8% from the previous year [3][2] - A positive surprise in earnings could lead to a stock price increase, while a miss could result in a decline [2] Estimate Revisions - The consensus EPS estimate has been revised 0.15% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4] - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that a positive or negative reading can indicate the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [6][7] Earnings Surprise History - Vertex has beaten consensus EPS estimates in two out of the last four quarters, with a recent surprise of -0.25% when it reported earnings of $3.98 against an expectation of $3.99 [12][13] Industry Comparison - Another company in the same industry, Travere Therapeutics (TVTX), is expected to report a loss of $0.55 per share, which represents a year-over-year increase of 68.8%, with revenues projected at $74.33 million, up 79.7% from the previous year [17] - Travere has an Earnings ESP of 11.18% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate, despite not having beaten estimates in the last four quarters [18]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Patria Investments, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - The earnings report is expected on May 2, 2025, with a consensus EPS estimate of $0.25, reflecting a +19.1% change year-over-year, and revenues projected at $81.42 million, up 34.4% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Patria Investments is lower than the consensus estimate, resulting in an Earnings ESP of -8%, indicating a bearish sentiment among analysts [10][11]. Historical Performance - In the last reported quarter, Patria Investments exceeded the expected EPS of $0.37 by delivering $0.58, resulting in a surprise of +56.76%. However, the company has only beaten consensus EPS estimates once in the last four quarters [12][13]. Conclusion - Given the current Earnings ESP and Zacks Rank of 4, Patria Investments does not appear to be a strong candidate for an earnings beat, suggesting that investors should consider additional factors before making investment decisions [16].

Core Viewpoint - Atmus Filtration Technologies (ATMU) is anticipated to report a year-over-year decline in earnings and revenues for the quarter ended March 2025, which could significantly influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for May 2, 2025, with a consensus estimate of $0.59 per share, reflecting a -1.7% change year-over-year. Revenues are projected to be $420.68 million, down 1.4% from the previous year [3][2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 1.02%, indicating a collective reassessment by analysts regarding the company's earnings outlook [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Atmus Filtration is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.09%. This suggests a bearish sentiment among analysts regarding the company's earnings prospects [10][11]. Historical Performance - In the last reported quarter, Atmus Filtration exceeded the expected earnings of $0.53 per share by delivering $0.58, resulting in a surprise of +9.43%. The company has beaten consensus EPS estimates in the last four quarters [12][13]. Investment Considerations - Despite the potential for an earnings beat, Atmus Filtration does not currently appear to be a compelling candidate for such an outcome, especially given its Zacks Rank of 4, which complicates predictions of beating the consensus EPS estimate [16][11].

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) is expected to report a year-over-year increase in earnings and revenues for the quarter ended March 2025, with a consensus EPS estimate of $0.14, reflecting a +16.7% change, and revenues projected at $2.73 billion, up 5.9% from the previous year [1][3]. Earnings Expectations - The stock price may increase if the actual earnings exceed expectations in the upcoming report scheduled for May 2, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.73% lower over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +106.62% for BrightSpring, suggesting analysts have become more optimistic about the company's earnings prospects [11]. - The company currently holds a Zacks Rank of 3, indicating a hold position, which suggests a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, BrightSpring exceeded the expected EPS of $0.19 by delivering $0.22, resulting in a surprise of +15.79%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13]. Industry Comparison - Another player in the Zacks Medical Services industry, Organon (OGN), is expected to report earnings of $0.92 per share, reflecting a year-over-year decline of -24.6%, with revenues projected at $1.54 billion, down 4.9% [17]. - Organon's consensus EPS estimate has been revised down by 1.7% over the last 30 days, and it currently has a negative Earnings ESP of -1.91%, making it difficult to predict a beat on the consensus EPS estimate [18].